Kite clinical trials

Acquired by Gilead Sciences, Oct 3, 2017 · source ↗

The registry lists 39 studies whose lead sponsor is Kite. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 39 of 39. All Gilead Sciences studies →

• Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruitingNCT06626919Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07887672Phase 3

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentRecruitingNCT07304154Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyRecruitingNCT07479797Phase 3

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• A Study of KITE-363 in Participants With Refractory Autoimmune DiseasesEnrolling by invitationNCT07038447Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell LymphomaRecruitingNCT04989803Phase 1/2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite StudiesEnrolling by invitationNCT05041309

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelAvailableNCT05776160

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAvailableNCT05776134

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.Active, not recruitingNCT05457010Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous TreatmentActive, not recruitingNCT06539338Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell LymphomaActive, not recruitingNCT06079164Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)CompletedNCT04880434Phase 2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingNCT06413498Phase 3

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaActive, not recruitingNCT06253663Phase 2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell LymphomaActive, not recruitingNCT05605899Phase 3

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT02625480Phase 1/2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted before Kite became part of Gilead Sciences

• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)CompletedNCT02601313Phase 2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted before Kite became part of Gilead Sciences

• Study of Brexucabtagene Autoleucel in Adults With Rare B-cell MalignanciesTerminatedNCT05537766Phase 2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaActive, not recruitingNCT04155749Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Active, not recruitingNCT05396885Phase 2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaCompletedNCT05459571Phase 2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin LymphomaCompletedNCT03105336Phase 2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted before Kite became part of Gilead Sciences

• Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT03391466Phase 3

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaActive, not recruitingNCT05371093Phase 3

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT04789408Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell LymphomaCompletedNCT03761056Phase 2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)CompletedNCT02614066Phase 1/2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted before Kite became part of Gilead Sciences

• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell LymphomaTerminatedNCT03704298Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaCompletedNCT02348216Phase 1/2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted before Kite became part of Gilead Sciences

• Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02926833Phase 1/2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted before Kite became part of Gilead Sciences

• Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell LymphomaTerminatedNCT04314843Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaCompletedNCT04002401Phase 2

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced CancersTerminatedNCT04025216Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaTerminatedNCT03624036Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Axicabtagene Ciloleucel Expanded Access StudyApproved for marketingNCT03153462

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted before Kite became part of Gilead Sciences

• Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03318861Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences

• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced CancersTerminatedNCT03139370Phase 1

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted before Kite became part of Gilead Sciences

• Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell MalignanciesApproved for marketingNCT04162756

  Sponsor listed in the registry: Kite, A Gilead Company · First submitted after Kite became part of Gilead Sciences